Treatment Of Patients With Social Anxiety Disorder

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 2

Conditions: Social Phobia

Treatments: Drug: paroxetine; Drug: GW876008

Study type: Interventional

Funder types: Industry

Identifiers

NCT00397722

CRH103390

Details and patient eligibility

About

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

Enrollment: 299 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• are diagnosed with generalized social anxiety disorder/social phobia.

Exclusion criteria

• have a diagnosis of major depressive disorder
• have a history of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.